Skip to main content Back to Top
Advertisement

6/26/2020

Pentamidine Isethionate

Reason for the Shortage

    • Fresenius Kabi had Nebupent and Pentam 300 on back order due to a short-term manufacturer delay.
    • Seton Pharmaceuticals had pentamidine isethionate injection on shortage due to high demand.

Available Products

    • NebuPent lyophilized powder for inhalation, Fresenius Kabi, 300 mg, 15 mL single dose vial, NDC 63323-0877-15
    • Pentam 300 lyophilized powder for injection, Fresenius Kabi, 300 mg, single dose vial, 10 count, NDC 63323-0113-10
    • Pentamidine isethionate lyophilized powder for inhalation, Seton Pharmaceuticals, 300 mg, single dose vial, 10 count, NDC 13925-0522-01
    • Pentamidine isethionate lyophilized powder for injection, Seton Pharmaceuticals, 300 mg, single dose vial, 10 count, NDC 13925-0515-10

Implications for Patient Care

    • Some clinicians may choose to use Pentam off-label via the nebulized route or NebuPent via the injectable route because both products contain identical ingredients. NebuPent and Pentam are FDA approved for different indications.

Updated

Updated June 26, 2020 by Leslie Jensen, PharmD, Drug Information Specialist. Created August 6, 2019 by Stephen Andrews, PharmD, BCPS, Drug Information Specialist. © 2020, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.